Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited

Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therap...

Full description

Bibliographic Details
Main Authors: Constantinescu, Cris S., Gershkovich, Pavel
Format: Article
Published: Wiley 2018
Online Access:https://eprints.nottingham.ac.uk/51035/
_version_ 1848798397407952896
author Constantinescu, Cris S.
Gershkovich, Pavel
author_facet Constantinescu, Cris S.
Gershkovich, Pavel
author_sort Constantinescu, Cris S.
building Nottingham Research Data Repository
collection Online Access
description Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therapeutic and psychoactive properties of this plant have been observed and used for centuries. Of the over 60 compounds that are unique to Cannabis sativa, the substances that have been attributed the greatest therapeutic potential are Δ9‐ tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which, used alone or combined with each other, have become approved drugs.
first_indexed 2025-11-14T20:19:07Z
format Article
id nottingham-51035
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:19:07Z
publishDate 2018
publisher Wiley
recordtype eprints
repository_type Digital Repository
spelling nottingham-510352020-05-04T19:43:23Z https://eprints.nottingham.ac.uk/51035/ Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited Constantinescu, Cris S. Gershkovich, Pavel Cannabinoids are compounds with pleiotropic properties that act on the cannabinoid receptors, CB1 and CB2, and are divided into endocannabinoids, the endogenous ligands of these receptors, synthetic cannabinoids and phytocannabinoids. The latter are derived from the plant Cannabis sativa. The therapeutic and psychoactive properties of this plant have been observed and used for centuries. Of the over 60 compounds that are unique to Cannabis sativa, the substances that have been attributed the greatest therapeutic potential are Δ9‐ tetrahydrocannabinol (THC) and cannabidiol (CBD), both of which, used alone or combined with each other, have become approved drugs. Wiley 2018-07-01 Article PeerReviewed Constantinescu, Cris S. and Gershkovich, Pavel (2018) Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited. European Journal of Neurology, 25 (7). pp. 905-906. ISSN 1351-5101 https://onlinelibrary.wiley.com/doi/abs/10.1111/ene.13658 doi:10.1111/ene.13658 doi:10.1111/ene.13658
spellingShingle Constantinescu, Cris S.
Gershkovich, Pavel
Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
title Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
title_full Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
title_fullStr Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
title_full_unstemmed Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
title_short Therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
title_sort therapeutic cannabinoids in multiple sclerosis: immunomodulation revisited
url https://eprints.nottingham.ac.uk/51035/
https://eprints.nottingham.ac.uk/51035/
https://eprints.nottingham.ac.uk/51035/